Table 2.

Brief overview of anti-CD20 antibodies and their main effector mechanisms.

	Rituximab	Ofatumumab	Ublituximab	Obinutuzumab
Generation	I	I	I	II
Type	Chimeric	Humanized	Chimeric	Humanized
ADCC	Intermediate	Intermediate	Very high	Very high
Direct Cytotoxicity	Low	Low	Intermediate	Very high
CDC	Intermediate	High	Intermediate	Low
ACDP	Intermediate	High	Very High	Very High

ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; ACDP, antibody-dependent cellular phagocytosis.